Italy
Metis Precision Medicine is a biotechnology startup based in Italy, founded in April 2017. The company has a strong focus on translating cancer research findings into precision medicine for cancer treatments. Backed by over three decades of research, METIS possesses in-depth knowledge of the biology and pathology driven by the oncogene MET, including cancer. The company is developing human anti-MET antibodies, particularly the hOA-DN30, which has shown exceptional effectiveness against cancer in pre-clinical settings. METIS holds the intellectual property of a suite of anti-MET monoclonal antibodies, known as the "Platform," targeting the MET oncogene.
With its slogan "The One Gene Company," METIS is committed to addressing diseases with significant unmet medical needs. The company operates as a B-corp, voluntarily meeting high standards of purpose, responsibility, and transparency, going beyond the goal of profit to maximize positive impacts on communities, the environment, and mankind.
The latest investment in METIS came through a Secondary Market investment on 17 March 2022 by Growth Engine. This investment underscores the confidence of investors in the potential of METIS in revolutionizing cancer treatments through precision medicine.
